Comparison

Human Recombinant FGFR-4 / Fc Chimera, soluble

Item no. CS-CRF019A
Manufacturer Cell Sciences
Amount 10 ug
Category
Type Proteins
Specific against Human (Homo sapiens)
Host Insect
Conjugate/Tag Fc
Purity > 90%, by SDS-PAGE and visualized by silver stain
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Similar products JTK2, TKF, hydroxyaryl-protein kinase, protein-tyrosine kinase, CD334, MGC20292, OTTHUMP00000161430, tyrosine kinase related to fibroblast growth factor receptor, tyrosylprotein kinase
Available
Manufacturer - Category
Biomolecules
Molecular Weight
170 kDa
Description
Recombinant human soluble FGFR-4 was fused with the Fc part of human IgG1. Human recombinant soluble FGFR-4/Fc is a disulfide-linked heterodimeric protein. The reduced form of human FGFR- 4/Fc is a monomer with a calculated molecular mass of approximately 65 kDa. As a result of glycosylation, the recombinant protein has a mass of 80-85 kDa. Fibroblast growth factors (FGFs) comprise a family of at least eighteen structurally related proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorgenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after ligand binding. Four distinct genes encoding closely related FGF receptors, FGF R1 - 4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1 - 3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the a isoform, or only IgII and IgIII, referred to as the b isoform. Only the a isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1 - 3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N-terminal half of the IgIII domain plus some intron sequences has also been reported for FGF R1. Mutations in FGF R1 - 3 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members are under investigation.
Formulation
Lyophilized
Reconstitution
The lyophilized sFGFR-4/Fc is soluble in water and most aqueous buffers. The lyophilized sFGFR-4/Fc should be reconstituted in PBS or medium to a concentration not lower than 50 ug/ml.
Biological Activity
Determined by its ability to inhibit human FGF basic-dependent proliferation on HUVE cells. The ED50 for this effect is typically at 15 - 30 ng/ml.
Endotoxin Level
< 0.1 ng per ug of sFGFR-4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 ug
Available: In stock
available

Delivery expected until 4/17/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close